Cargando…

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer

PURPOSE: Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is associated with high invasiveness, high metastatic occurrence and poor prognosis. Protein tyrosine kinase 7 (PTK7) plays an important role in multiple cancers. However, the role of PTK7 in TNBC has not be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Nai-Peng, Qiao, Shu, Jiang, Shan, Hu, Jin-Lin, Wang, Ting-Ting, Liu, Wen-Wen, Qin, Yan, Wang, Ya-Nan, Zheng, Li-Shuang, Zhang, Jin-Chao, Ma, Yong-Ping, Chen, Bao-Ping, Shi, Jian-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339706/ https://www.ncbi.nlm.nih.gov/pubmed/34367983 http://dx.doi.org/10.3389/fonc.2021.699889

Ejemplares similares

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

LAMC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer
por: Tong, Dongdong, et al.
Publicado: (2023)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors
por: Widatalla, Sarrah E, et al.
Publicado: (2019)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
por: Chen, Yang, et al.
Publicado: (2018)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers
por: Limsakul, Praopim, et al.
Publicado: (2023)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
por: Weng, Tian-Hao, et al.
Publicado: (2020)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Sirinian, Chaido, et al.
Publicado: (2021)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun
por: Li, Ying, et al.
Publicado: (2016)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1
por: Wang, Chen, et al.
Publicado: (2018)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors
por: Yang, Ying, et al.
Publicado: (2022)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
por: Cao, Wen-Ming, et al.
Publicado: (2015)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer
por: Liu, Bing, et al.
Publicado: (2016)

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy
por: Weng, Qiaoyou, et al.
Publicado: (2021)

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
por: Han, Weidong, et al.
Publicado: (2011)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019)

CAPE-pNO(2) Inhibited the Growth and Metastasis of Triple-Negative Breast Cancer via the EGFR/STAT3/Akt/E-Cadherin Signaling Pathway
por: Huang, Qin, et al.
Publicado: (2019)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0pqvtjdfsqhonbprtf6e8u9n4f